Rapid antidepressants stimulate the decoupling of GABA B receptors from GIRK/Kir3 channels through increased protein stability of 14-3-3η

Molecular Psychiatry

Volumn 20, Issue 3, 2015, Pages 298-310

  Workman, E R ^a   Haddick, P C G ^b   Bush, K ^a   Dilly, G A ^a   Niere, F ^a   Zemelman, B V ^a   Raab Graham, K F ^a  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 5 PHOSPHONOVALERIC ACID; 4 AMINOBUTYRIC ACID B RECEPTOR; 4 BENZYL ALPHA (4 HYDROXYPHENYL) BETA METHYL 1 PIPERIDINEPROPANOL; G PROTEIN COUPLED INWARDLY RECTIFYING POTASSIUM CHANNEL; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PROTEIN 14 3 3; 2-AMINO-5-PHOSPHOPENTANOIC ACID; AMINO ACID RECEPTOR BLOCKING AGENT; ANTIDEPRESSANT AGENT; MESSENGER RNA; PHENOL DERIVATIVE; PIPERIDINE DERIVATIVE; VALINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN LEVEL; CONTROLLED STUDY; DEPRESSION; HIPPOCAMPUS; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STABILITY; RAT; RECEPTOR BLOCKING; SIGNAL TRANSDUCTION; ANALOGS AND DERIVATIVES; ANIMAL; CELL CULTURE; CYTOLOGY; DISEASE MODEL; DRUG EFFECTS; DRUG THERAPY; GENETIC TRANSDUCTION; GENETICS; IMMUNOPRECIPITATION; MENTAL STRESS; METABOLISM; NERVE CELL; NEWBORN; PATHOLOGY; PATHOPHYSIOLOGY; PREFRONTAL CORTEX; PSYCHOLOGY; SPRAGUE DAWLEY RAT; SWIMMING; SYNAPTOSOME;

14-3-3 PROTEINS; ANIMALS; ANIMALS, NEWBORN; ANTIDEPRESSIVE AGENTS; CELLS, CULTURED; DISEASE MODELS, ANIMAL; EXCITATORY AMINO ACID ANTAGONISTS; G PROTEIN-COUPLED INWARDLY-RECTIFYING POTASSIUM CHANNELS; IMMUNOPRECIPITATION; MALE; MICE; NEURONS; PHENOLS; PIPERIDINES; PREFRONTAL CORTEX; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, GABA-B; RNA, MESSENGER; STRESS, PSYCHOLOGICAL; SWIMMING; SYNAPTOSOMES; TRANSDUCTION, GENETIC; VALINE;

EID: 84924655016     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/mp.2014.165     Document Type: Article

References (80)

1. Ferrari AJ, Charlson FJ, Norman RE, Patten SB, Freedman G, Murray CJ, et al. Burden of depressive disorders by country, sex, age, and year: findings from the global burden of disease study 2010. PLoS Med 2013; 10: e1001547
2. Kessler RC, Bromet EJ. The epidemiology of depression across cultures. Annu Rev Public Health 2013; 34: 119-138
3. Levinstein MR, Samuels BA. Mechanisms underlying the antidepressant response and treatment resistance. Front Behav Neurosci 2014; 8: 208
4. Duman RS, Li N, Liu RJ, Duric V, Aghajanian G. Signaling pathways underlying the rapid antidepressant actions of ketamine. Neuropharmacology 2012; 62: 35-41
5. Samuels BA, Leonardo ED, Gadient R, Williams A, Zhou J, David DJ, et al. Modeling treatment-resistant depression. Neuropharmacology 2011; 61: 408-413
6. Pochwat B, Palucha-Poniewiera A, Szewczyk B, Pilc A, Nowak G. NMDA antagonists under investigation for the treatment of major depressive disorder. Expert Opin Invest Drugs 2014; 23: 1181-1192
7. Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, et al. Acute and longer-Term outcomes in depressed outpatients requiring one or several treatment steps: a STAR.D report. Am J Psychiatry 2006; 163: 1905-1917
8. Rush AJ, Trivedi MH, Wisniewski SR, Stewart JW, Nierenberg AA, Thase ME, et al. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med 2006; 354: 1231-1242
9. Holtzheimer PE, Mayberg HS. Deep brain stimulation for psychiatric disorders. Annu Rev Neurosci 2011; 34: 289-307
10. Holtzheimer PE, Mayberg HS. Stuck in a rut: rethinking depression and its treatment. Trends Neurosci 2011; 34: 1-9
11. Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 2000; 47: 351-354
12. Zarate CA Jr., Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, et al. A randomized trial of an N-methyl-D-Aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 2006; 63: 856-864
13. aan het Rot M, Collins KA, Murrough JW, Perez AM, Reich DL, Charney DS, et al. Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol Psychiatry 2010; 67: 139-145
14. Papp M, Moryl E. Rewarding properties of non-competitive and competitive NMDA antagonists as measured by place preference conditioning in rats. Pol J Pharmacol 1994; 46: 79-81
15. Skolnick P, Popik P, Trullas R. Glutamate-based antidepressants: 20 years on. Trends Pharmacol Sci 2009; 30: 563-569
16. Pozzi L, Dorocic IP, Wang X, Carlen M, Meletis K. Mice lacking NMDA receptors in parvalbumin neurons display normal depression-related behavior and response to antidepressant action of NMDAR antagonists. PLoS One 2014; 9: e83879
17. Dutar P, Nicoll RA. A physiological role for GABAB receptors in the central nervous system. Nature 1988; 332: 156-158
18. Cryan JF, Slattery DA. GABAB receptors and depression. Current status. Adv Pharmacol 2010; 58: 427-451
19. Workman ER, Niere F, Raab-Graham KF. mTORC1-dependent protein synthesis underlying rapid antidepressant effect requires GABABR signaling. Neuropharmacology 2013; 73: 192-203
20. Li N, Lee B, Liu RJ, Banasr M, Dwyer JM, Iwata M, et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 2010; 329: 959-964
21. Couve A, Kittler JT, Uren JM, Calver AR, Pangalos MN, Walsh FS, et al. Association of GABA(B) receptors and members of the 14-3-3 family of signaling proteins. Mol Cell Neurosci 2001; 17: 317-328
22. Laffray S, Bouali-Benazzouz R, Papon MA, Favereaux A, Jiang Y, Holm T, et al. Impairment of GABAB receptor dimer by endogenous 14-3-3zeta in chronic pain conditions. EMBO J 2012; 31: 3239-3251
23. Foote M, Zhou Y. 14-3-3 proteins in neurological disorders. Int J Biochem Mol Biol 2012; 3: 152-164
24. Quinlan EM, Olstein DH, Bear MF. Bidirectional, experience-dependent regulation of N-methyl-D-Aspartate receptor subunit composition in the rat visual cortex during postnatal development. Proc Natl Acad Sci USA 1999; 96: 12876-12880
25. Thorson JA, Yu LW, Hsu AL, Shih NY, Graves PR, Tanner JW, et al. 14-3-3 proteins are required for maintenance of Raf-1 phosphorylation and kinase activity. Mol Cell Biol 1998; 18: 5229-5238
26. Shaner NC, Campbell RE, Steinbach PA, Giepmans BN, Palmer AE, Tsien RY. Improved monomeric red, orange and yellow fluorescent proteins derived from Discosoma sp. red fluorescent protein. Nat Biotechnol 2004; 22: 1567-1572
27. Varga V, Losonczy A, Zemelman BV, Borhegyi Z, Nyiri G, Domonkos A, et al. Fast synaptic subcortical control of hippocampal circuits. Science 2009; 326: 449-453
28. Grieger JC, Choi VW, Samulski RJ. Production and characterization of adenoassociated viral vectors. Nat Protoc 2006; 1: 1412-1428
29. Ma T, Hoeffer CA, Capetillo-Zarate E, Yu F, Wong H, Lin MT, et al. Dysregulation of the mTOR pathway mediates impairment of synaptic plasticity in a mouse model of Alzheimer's disease. PLoS One 2010; 5, e12845
30. Hayashi T, Huganir RL. Tyrosine phosphorylation and regulation of the AMPA receptor by SRC family tyrosine kinases. J Neurosci 2004; 24: 6152-6160
31. Dieterich DC, Hodas JJ, Gouzer G, Shadrin IY, Ngo JT, Triller A, et al. In situ visualization and dynamics of newly synthesized proteins in rat hippocampal neurons. Nat Neurosci 2010; 13: 897-905
32. Dieterich DC, Lee JJ, Link AJ, Graumann J, Tirrell DA, Schuman EM. Labeling, detection and identification of newly synthesized proteomes with bioorthogonal non-canonical amino-Acid tagging. Nat Protoc 2007; 2: 532-540
33. Dieterich DC, Link AJ, Graumann J, Tirrell DA, Schuman EM. Selective identification of newly synthesized proteins in mammalian cells using bioorthogonal noncanonical amino acid tagging (BONCAT). Proc Natl Acad Sci USA 2006; 103: 9482-9487
34. Tsutsui H, Karasawa S, Okamura Y, Miyawaki A. Improving membrane voltage measurements using FRET with new fluorescent proteins. Nat Methods 2008; 5: 683-685
35. Sosanya NM, Huang PP, Cacheaux LP, Chen CJ, Nguyen K, Perrone-Bizzozero NI, et al. Degradation of high affinity HuD targets releases Kv11 mRNA from miR-129 repression by mTORC1. J Cell Biol 2013; 202: 53-69
36. Raab-Graham KF, Haddick PC, Jan YN, Jan LY. Activity- And mTOR-dependent suppression of Kv11 channel mRNA translation in dendrites. Science 2006; 314: 144-148
37. Bolte S, Cordelieres FP. A guided tour into subcellular colocalization analysis in light microscopy. J Microsc 2006; 224: 213-232
38. Porsolt RD, Le Pichon M, Jalfre M. Depression: a new animal model sensitive to antidepressant treatments. Nature 1977; 266: 730-732
39. Can A, Dao DT, Terrillion CE, Piantadosi SC, Bhat S, Gould TD. The tail suspension test. J Vis Exp 2012; 59: e3769
40. Santarelli L, Saxe M, Gross C, Surget A, Battaglia F, Dulawa S, et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 2003; 301: 805-809
41. Surget A, Saxe M, Leman S, Ibarguen-Vargas Y, Chalon S, Griebel G, et al. Drugdependent requirement of hippocampal neurogenesis in a model of depression and of antidepressant reversal. Biol Psychiatry 2008; 64: 293-301
42. Yalcin I, Belzung C, Surget A. Mouse strain differences in the unpredictable chronic mild stress: a four-Antidepressant survey. Behav Brain Res 2008; 193: 140-143
43. Nosyreva E, Szabla K, Autry AE, Ryazanov AG, Monteggia LM, Kavalali ET. Acute suppression of spontaneous neurotransmission drives synaptic potentiation. J Neurosci 2013; 33: 6990-7002
44. Duman RS, Aghajanian GK. Synaptic dysfunction in depression: potential therapeutic targets. Science 2012; 338: 68-72
45. Trullas R, Folio T, Young A, Miller R, Boje K, Skolnick P. 1-Aminocyclopropanecarboxylates exhibit antidepressant and anxiolytic actions in animal models. Eur J Pharmacol 1991; 203: 379-385
46. Boast C. Neuroprotection after brain ischemia: role of competitive NMDA antagonists. Neuol Neurobiol 1988; 46: 8
47. Loscher W, Nolting B, Honack D. Evaluation of CPP, a selective NMDA antagonist, in various rodent models of epilepsy. Comparison with other NMDA antagonists, and with diazepam and phenobarbital. Eur J Pharmacol 1988; 152: 9-17
48. Schoepp DD, Gamble AY, Salhoff CR, Johnson BG, Ornstein PL. Excitatory amino acid-induced convulsions in neonatal rats mediated by distinct receptor subtypes. Eur J Pharmacol 1990; 182: 421-427
49. Kovacs Z, Czurko A, Kekesi KA, Juhasz G. Intracerebroventricularly administered lipopolysaccharide enhances spike-wave discharges in freely moving WAG/ Rij rats. Brain Res Bull 2011; 85: 410-416
50. Chapman AG, Graham JL, Patel S, Meldrum BS. Anticonvulsant activity of two orally active competitive N-methyl-D-Aspartate antagonists, CGP 37849 and CGP 39551, against sound-induced seizures in DBA/2 mice and photically induced myoclonus in Papio papio. Epilepsia 1991; 32: 578-587
51. Guerrini L, Molteni A, Wirth T, Kistler B, Blasi F. Glutamate-dependent activation of NF-kappaB during mouse cerebellum development. J Neurosci 1997; 17: 6057-6063
52. Loeb C, Patrone A, Besio G, Balestrino M, Mainardi P. The antiepileptic effect of low-dose amino-phosphono-valeric acid (APV) is not enhanced by phosphatidylserine association. Seizure 1993; 2: 309-310
53. Loeb C, Patrone A, Besio G, Balestrino M, Mainardi P. The excitatory amino acid antagonist amino-phosphono-valeric acid (APV) provides protection against penicillin-induced epileptic activity in the rat. Epilepsy Res 1990; 6: 249-251
54. Leung LS, Shen B. N-methyl-D-Aspartate receptor antagonists are less effective in blocking long-Term potentiation at apical than basal dendrites in hippocampal CA1 of awake rats. Hippocampus 1999; 9: 617-630
55. Porsolt RD. Animal model of depression. Biomedicine 1979; 30: 139-140
56. Porsolt RD, Bertin A, Blavet N, Deniel M, Jalfre M. Immobility induced by forced swimming in rats: effects of agents which modify central catecholamine and serotonin activity. Eur J Pharmacol 1979; 57: 201-210
57. Margeta-Mitrovic M, Jan YN, Jan LY. A trafficking checkpoint controls GABA(B) receptor heterodimerization. Neuron 2000; 27: 97-106
58. Padgett CL, Slesinger PA. GABAB receptor coupling to G-proteins and ion channels. Adv Pharmacol 2010; 58: 123-147
59. Chung HJ, Qian X, Ehlers M, Jan YN, Jan LY. Neuronal activity regulates phosphorylation-dependent surface delivery of G protein-Activated inwardly rectifying potassium channels. Proc Natl Acad Sci USA 2009; 106: 629-634
60. McClung CA, Nestler EJ. Neuroplasticity mediated by altered gene expression. Neuropsychopharmacology 2008; 33: 3-17
61. Nestler EJ, Gould E, Manji H, Buncan M, Duman RS, Greshenfeld HK, et al. Preclinical models: status of basic research in depression. Biol Psychiatry 2002; 52: 503-528
62. Berton O, McClung CA, Dileone RJ, Krishnan V, Renthal W, Russo SJ, et al. Essential role of BDNF in the mesolimbic dopamine pathway in social defeat stress. Science 2006; 311: 864-868
63. Duclot F, Kabbaj M. Individual differences in novelty seeking predict subsequent vulnerability to social defeat through a differential epigenetic regulation of brainderived neurotrophic factor expression. J Neurosci 2013; 33: 11048-11060
64. Kabbaj M, Norton CS, Kollack-Walker S, Watson SJ, Robinson TE, Akil H. Social defeat alters the acquisition of cocaine self-Administration in rats: role of individual differences in cocaine-Taking behavior. Psychopharmacology 2001; 158: 382-387
65. Costa-Nunes J, Zubareva O, Araujo-Correia M, Valenca A, Schroeter CA, Pawluski JL, et al. Altered emotionality, hippocampus-dependent performance and expression of NMDA receptor subunit mRNAs in chronically stressed mice. Stress 2014; 17: 108-116
66. Perron A, Mutoh H, Akemann W, Gautam SG, Dimitrov D, Iwamoto Y, et al. Second and third generation voltage-sensitive fluorescent proteins for monitoring membrane potential. Front Mol Neurosci 2009; 2: 5
67. Mizuno H, Mal TK, Tong KI, Ando R, Furuta T, Ikura M, et al. Photo-induced peptide cleavage in the green-To-red conversion of a fluorescent protein. Mol Cell 2003; 12: 1051-1058
68. Banerjee S, Neveu P, Kosik KS. A coordinated local translational control point at the synapse involving relief from silencing and MOV10 degradation. Neuron 2009; 64: 871-884
69. Wang DO, Kim SM, Zhao Y, Hwang H, Miura SK, Sossin WS, et al. Synapse- And stimulus-specific local translation during long-Term neuronal plasticity. Science 2009; 324: 1536-1540
70. Steru L, Chermat R, Thierry B, Simon P. The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology 1985; 85: 367-370
71. Duan S, Gao R, Xing Q, Du J, Liu Z, Chen Q, et al. A family-based association study of schizophrenia with polymorphisms at three candidate genes. Neurosci Lett 2005; 379: 32-36
72. Grover D, Verma R, Goes FS, Mahon PL, Gershon ES, McMahon FJ, et al. Familybased association of YWHAH in psychotic bipolar disorder. Am J Med Genet B Neuropsychiatr Genet 2009; 150B: 977-983
73. Toyooka K, Muratake T, Tanaka T, Igarashi S, Watanabe H, Takeuchi H, et al. 14-3-3 protein eta chain gene (YWHAH) polymorphism and its genetic association with schizophrenia. Am J Med Genet 1999; 88: 164-167
74. Wong AH, Macciardi F, Klempan T, Kawczynski W, Barr CL, Lakatoo S, et al. Identification of candidate genes for psychosis in rat models, and possible association between schizophrenia and the 14-3-3eta gene. Mol Psychiatry 2003; 8: 156-166
75. Wiltfang J, Otto M, Baxter HC, Bodemer M, Steinacker P, Bahn E, et al. Isoform pattern of 14-3-3 proteins in the cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. J Neurochem 1999; 73: 2485-2490
76. Li XH, Noguchi A, Nishida T, Takahashi H, Zheng Y, Yang XH, et al. Cytoplasmic expression of p33ING1b is correlated with tumorigenesis and progression of head and neck squamous cell carcinoma. Histol Histopathol 2011; 26: 597-607
77. Papp M, Moryl E. Antidepressant activity of non-competitive and competitive NMDA receptor antagonists in a chronic mild stress model of depression. Eur J Pharmacol 1994; 263: 1-7
78. Li N, Liu RJ, Dwyer JM, Banasr M, Lee B, Son H, et al. Glutamate N-methyl-Daspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure. Biol Psychiatry 2011; 69: 754-761
79. Autry AE, Adachi M, Nosyreva E, Na ES, Los MF, Cheng PF, et al. NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature 2011; 475: 91-95
80. Donahue RJ, Muschamp JW, Russo SJ, Nestler EJ, Carlezon WA Jr. Effects of striatal deltaFosB overexpression and ketamine on social defeat stress-induced anhedonia in mice. Biol Psychiatry 2014; 76: 550-558